The trade name of shingles vaccine (recombinant zoster vaccine) is SHINGRIX, which was developed by GlaxoSmithKline. Its product was firstly approved in China in 2020. Shingles vaccine is suitable for adults aged 50 years and over to protect against shingles (herpes zoster). The recombinant zoster vaccine has been listed in the Chinese market. By July 2022, GlaxoSmithKline Biologicals is the only manufacturer in the Chinese Shingles Vaccine market.
According to CRI’s market research, since Shingles Vaccine entered the Chinese market in 2020, its annual sales value reached CNY19 million(US$2.85 million), and its annual sales volume reached nearly 12,000 doses. Therefore, the development prospects are quite good.
According to CRI analysis, from 2022 to 2031, as Shingles Vaccine market expands, its sales will continue to grow. Compared with Merck’s Zostavax, SHINGRIX has better preventive effects and faster replacement velocity. Therefore, as the market share of Shingles Vaccine will gradually increase, and sales and sales volume will also increase.

Topics Covered:
The impact of COVID-19 on China’s Shingles Vaccine market
Sales volume and value of China’s Shingles Vaccine 2020-2021
Sales volume and value of Shingles Vaccine by regions in China 2020-2021
Competitive landscape of China’s Shingles Vaccine market
Prices of Shingles Vaccine in China
Prices of Shingles Vaccine in China by regions in China
Analysis on factors affecting the development of China’s Shingles Vaccine market
Prospect of China’s Shingles Vaccine market from 2022 to 2031